Article citationsMore >>

Ball MP, Coons VB, Buchanan RW. A program for treating olanzapine-related weight gain. Psychiatr Serv. 2001; 52: 967-969.

has been cited by the following article:

Article

Insulin Resistance One Mechanism Two Presentations: Olanzapine Induced DKA and Hypertriglyceridemia

1Department of Internal Medicine, State University of New York, Downstate- Health Science University, Brooklyn, NY, USA - 11203

2Division of Pulmonology, State University of New York, Downstate- Health Science University, Brooklyn, NY, USA - 11203


American Journal of Medical Case Reports. 2021, Vol. 9 No. 2, 131-133
DOI: 10.12691/ajmcr-9-2-8
Copyright © 2020 Science and Education Publishing

Cite this paper:
Louis Costanzo, Chetana Pendkar, Amara Shafi, Joseph Gorga. Insulin Resistance One Mechanism Two Presentations: Olanzapine Induced DKA and Hypertriglyceridemia. American Journal of Medical Case Reports. 2021; 9(2):131-133. doi: 10.12691/ajmcr-9-2-8.

Correspondence to: Louis  Costanzo, Department of Internal Medicine, State University of New York, Downstate- Health Science University, Brooklyn, NY, USA - 11203. Email: louis.costanzo@downstate.edu

Abstract

Patients taking antipsychotic medications have a well-established increased risk of developing metabolic syndrome. These medications interfere with an intracellular signaling pathway leading to insulin resistance; that of which can lead to dangerous complications including diabetic ketoacidosis (DKA) and severe hypertriglyceridemia. We report a case of a 21-year-old man who developed DKA and severe hypertriglyceridemia secondary to the use of olanzapine used for the management of schizophrenia.

Keywords